Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

However while melanoma is relatively rare, lung cancer is by far the UK’s biggest cancer killer. It causes 22% of all cancer deaths in men and women, more than breast and bowel cancer combined.

Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

All attendees shared a vested interest in the rapidly evolving cancer treatment landscape. Nowhere was the vastness of that ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), and Merck (NYSE: MRK). Alphabet's problem isn't its financial results; in that ...